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Abstract
Background: Developing strategies for controlling the severity of pandemic influenza is a global
public health priority. In the event of a pandemic there may be a place for inexpensive, readily
available, effective adjunctive therapies to support containment strategies such as prescription
antivirals, vaccines, quarantine and restrictions on travel. Inactivation of virus in the intranasal
environment is one possible approach. The work described here investigated the sensitivity of
influenza viruses to low pH, and the activity of low pH nasal sprays on the course of an influenza
infection in the ferret model.
Methods: Inactivation of influenza A and avian reassortment influenza was determined using in vitro
solutions tests. Low pH nasal sprays were tested using the ferret model with an influenza A Sydney/
5/97 challenge. Clinical measures were shed virus, weight loss and body temperature.
Results: The virus inactivation studies showed that influenza viruses are rapidly inactivated by
contact with acid buffered solutions at pH 3.5. The titre of influenza A Sydney/5/97 [H3N2] was
reduced by at least 3 log cycles with one minute contact with buffers based on simple acid mixtures
such as L-pyroglutamic acid, succinic acid, citric acid and ascorbic acid. A pH 3.5 nasal gel
composition containing pyroglutamic acid, succinic acid and zinc acetate reduced titres of influenza
A Hong Kong/8/68 [H3N2] by 6 log cycles, and avian reassortment influenza A/Washington/897/
80 X A Mallard/New York/6750/78 [H3N2] by 5 log cycles, with 1 min contact.
Two ferret challenge studies, with influenza A Sydney/5/97, demonstrated a reduction in the
severity of the disease with early application of low pH nasal sprays versus a saline control. In the
first study there was decreased weight loss in the treatment groups. In the second study there were
reductions in virus shedding and weight loss, most notably when a gelling agent was added to the
low pH formulation.
Conclusion: These findings indicate the potential of a low pH nasal spray as an adjunct to current
influenza therapies, and warrant further investigation in humans.
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Background
Pandemic influenza, whether from new avian strains or
from reassortment within existing strains, is of growing
concern [1-3]. If an influenza pandemic of a virulent
strain were to emerge, it would rapidly spread around the
globe with potential to overwhelm health services. The
logistics of mass distribution, coupled with the known
limitations of current treatments, mean there is a risk that
recommended therapeutic strategies against influenza
may leave a significant proportion of the population
underprotected [2]. Vaccines are, by definition, one step
behind the latest mutation of the influenza virus. Antiviral
drugs, such as the neuraminidase inhibitors Oseltamivir
and Zanamivir, are effective treatments, provided they can
be given to patients early enough [4]. There may be prac-
tical limitations to the fast supply of these prescription-
only drugs to patients at the optimum disease interven-
tion point during a pandemic. Furthermore, there is the
concern over potential for development of viral resistance
to these drug interventions. As most patients will deal
with influenza at home, a readily available, safe and effec-
tive influenza therapy to reduce the severity of the disease,
from the early stages of infection, has the potential to be
of considerable value in the event of an epidemic or pan-
demic.
Our studies investigate whether a low pH nasal gel com-
position could inactivate influenza virus. Some respira-
tory viruses are known to be sensitive to low pH [5,6].
Rhinoviruses, in particular, are inactivated by acidic con-
ditions, and this is thought to be due to conformational
changes in capsid proteins at pH < 6.2, leading to loss of
the VP4 subunit [7]. The haemagglutinin structure of
influenza virus is known to be pH sensitive and undergoes
conformational changes under acidic conditions [8]. The
aim of the work reported here was to determine whether
a low pH intranasal spray could be effective against influ-
enza virus, initially using in vitro solution tests to deter-
mine susceptibility of virus to contact with low pH
solutions, and then ferret model preclinical studies.
Methods
Test formulations
A range of prototype nasal spray formulations was tested
(table 1). They were all pH 3.5, buffered, aqueous solu-
tions, based on L-pyroglutamic acid (PCA) with variable
secondary acids; ascorbic acid, citric acid, phytic acid and
succinic acid. Additionally, some formulations contained
zinc acetate dihydrate. Some of the formulations were
tested with mucoadhesive gelling agents, Carbopol 980
(Noveon, Cleveland) or hydroxypropylmethyl cellulose
(HPMC). Carbopol-containing formulations were not
tested in vitro due to pipetting difficulties caused by a vis-
cosity increase of the carbomer at the neutralisation stage
of the solution tests.
Virus assay
Influenza A Sydney/5/97 [H3N2] solution tests were con-
ducted by Retroscreen Virology, London, UK. Two hun-
dred microlitres of stock virus at approximately 106
TCID50 in foetal calf serum (FCS) were mixed with 200 µl
of test product at 24°C. After 1 minute, the mixture was
neutralised by 10-fold dilutions in Minimal Essential
Medium (MEM), and assayed for infective virus. The virus
was quantified by titration in quadruplicate on Madin
Derby Canine Kidney (MDCK) cells in (MEM) with 2.5
ug/ml Tosyl Phenylalanyl Chloromethyl Ketone (TPCK)-
treated trypsin, followed by agglutination assay using Tur-
key Red Blood Cells. Controls without virus were
included to test for carry-over cytopathicity of the product
into the virus assay. The TCID50 was calculated using the
Karber equation [9].
Influenza A Hong Kong/8/68 [H3N2] (ATCC VR-544)
and avian reassortment influenza solution tests were con-
ducted by ATS Labs, MN, USA. The avian reassortment
virus used was A/Washington/897/80 X A Mallard/New
York/6750/78 [H3N2] (ATCC VR-2072), prepared origi-
nally by Murphy et al (10). Five hundred microlitres of
stock virus at approximately 105–106 TCID50 in FCS were
mixed with 4.5 ml of test product at 24°C. After 1 minute,
the mixture was neutralised by 10-fold dilutions in Mini-
mal Essential Medium (MEM), and assayed for infective
virus in quadruplicate, on monolayers of Rhesus Monkey
Kidney cells (RMK) with MEM supplemented with 2%
heat inactivated fetal bovine serum (FBS). Controls with-
out virus were included to test for carry-over cytopathicity
of the product into the virus assay.
Table 1: Composition of formulations tested in solution tests and in vivo influenza model
Formulation tested Code Solution test in vivo model
PCA/ascorbic acid/phytic acid PAP xa
PCA/ascorbic acid/zinc acetate dihydrate PAZ xa
PCA/citric acid/phytic acid PCP xa xa
PCA/ascorbic acid/phytic acid/Carbopol 980 PAPC xa
PCA/ascorbic acid/zinc acetate/Carbopol 980 PAZC xa
PCA/citric acid/phytic acid/Carbopol 980 PCPC xa
PCA/succinic acid/zinc acetate/HPMC PSZH xb
a Conducted by Retroscreen Virology, London, UK.
b Conducted by ATS Labs, Eagan, MN, USARespiratory Research 2007, 8:38 http://respiratory-research.com/content/8/1/38
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In vivo influenza studies
Female ferrets (either albino or fitch), approximately 6
months old, and body weight 700–800 g, were obtained
from Highgate Farm, Market Rasen, UK. Animals were
identified by an electronic chip inserted under the skin.
They were maintained under controlled diet (Diet F; Spe-
cial Diet Services, Witham, UK). Prior to the study, blood
samples were taken from the animals and a haemaggluti-
nin inhibition assay was performed against Influenza A/
Sydney/5/97 to confirm seronegativity to the virus strain.
All animal work was conducted in accordance with UK
Home Office guidelines. In addition, a thorough review of
alternatives was conducted, in line with Procter and Gam-
ble policy of humane treatment and commitment to
refinement, reduction and replacement of animal models.
In this case there were no viable alternatives nor existing
research.
The challenge virus was Influenza A Sydney/5/97 [H3N2],
obtained as an allantoic stock from the Retroscreen repos-
itory (Retroscreen Virology, London, UK). It was prepared
as a 103.25 TCID50/0.1 ml stock in Phosphate buffered
saline (PBS). It was administered intranasally to the ani-
mals using a pipette. Treatment products were filled into
Valois VP7 nasal pump sprays, dosing 100 ml.
Treatments
The first study was conducted with 24 ferrets, divided into
4 groups of 6 animals (table 2).
Group 1 was challenged with 0.1 ml of influenza virus
stock per nostril on day 0, and received 0.1 ml of PAPC
nasal spray per nostril 5 minutes later. The animals subse-
quently received a once-daily intranasal dose of test for-
mulation from day 1 to day 6.
Group 2 received a pre-infection application of 0.1 ml per
nostril of PAPC nasal spray, followed by virus challenge 5
minutes later.
Group 3 had the same post-infection regime as group 1,
with nasal spray PAZC.
Group 4 was a control group. On day 0, they received an
intranasal dose of 0.1 ml PBS per nostril, followed by
virus challenge 5 minutes later.
A second study was conducted with 18 ferrets, divided
into 3 groups of 6 animals (table 3). The purpose was to
determine whether addition of a mucoadhesive polymer
(Carbopol 980) affected efficacy of the low pH spray.
Group 1 received 0.1 ml of stock influenza virus per nos-
tril on day 0. Five minutes later, they received 0.1 ml per
nostril of Carbopol 980 gel nasal spray PAPC. The animals
subsequently received once-daily 0.1 ml intranasal
administrations of the test formulations from day 1 to day
5.
Group 2 had the same administration regime as group 2,
and received non-mucoadhesive spray PCP.
Group 3 was a control group. They had the same admin-
istration regime as the treatment groups, and received 0.1
ml of PBS per nostril. The animals subsequently received
once-daily administrations of 0.1 ml PBS from day 1 to
day 5.
In both studies, the animals were monitored daily for clin-
ical symptoms; fever (by rectal temperature), weight
change, and nasal washes were conducted to estimate
virus shedding. The nasal washes were performed under
anaesthesia by instillation of 1.0 ml of PBS into each nos-
tril and collection of aspirated fluid. Haemagglutinin
assay on MDCK cells was used to determine virus titre in
the nasal wash samples.
Statistical analysis
For the virus data, ANalysis Of VAriance (ANOVA) meth-
ods were applied. For temperature and body weight meas-
ures, the readings at day 0 were used as a baseline
covariate in ANalysis of COVAriance (ANCOVA). Model
diagnostics were applied to check the ANOVA and
ANCOVA model assumptions. Adjustments for multiple
treatment comparisons were made (Sidak) and testing
was performed at the 10% significance level.
Table 2: Assignment of animals to treatment and control groups
Ferret 
assignment
n Day 0 5 min Day 1 Day 2 Day 3 Day 4 Day 5 Day 6
Group 1 6 virus challenge 0.1 ml PAPC 0.1 ml PAPC 0.1 ml PAPC 0.1 ml PAPC 0.1 ml PAPC 0.1 ml PAPC 0.1 ml PAPC
Group 2 6 0.1 ml PAPC Virus challenge
Group 3 6 virus challenge 0.1 ml PAZC 0.1 ml PAZC 0.1 ml PAZC 0.1 ml PAZC 0.1 ml PAZC 0.1 ml PAZC 0.1 ml PAZC
Group 4 
control
6 0.1 ml PBS Virus challengeRespiratory Research 2007, 8:38 http://respiratory-research.com/content/8/1/38
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Results
All low pH compositions tested rapidly inactivated
Human Influenza A. In the first series of experiments (fig
1), the PBS control level of virus was 105 TCID50. Compo-
sitions PAP and PCP reduced virus titre by about 3 log
cycles with one minute exposure; whereas, with the zinc
acetate composition, PAZ, there was no recovered virus,
indicating at least 5 log cycles reduction versus control.
In the second series of experiments with formula PSZH
(fig 2), there was no detectable Influenza A or Avian influ-
enza after 1 min exposure, indicating 6 log cycle and 5 log
cycle reductions respectively versus controls.
Ferrets infected with influenza develop a self-limited dis-
ease with signs similar to those of human influenza [11].
Typically these are; fever, nasal symptoms, general leth-
argy and decreased rate of weight gain. In an experimental
model, the signs usually peak at 48 hours after initial virus
challenge. This coincides with an increase in infectious
virus shedding and the number of inflammatory cells
detected in nasal lavage samples.
In the first study, virus shedding in the control group
peaked at 103.1TCID50 at 48 hours. None of the active
sprays significantly reduced virus levels. The PAZC spray
group showed a 0.6 log TCID50 lower virus titre vs control,
but this did not reach statistical significance (p = 0.994).
There was an increase in mean body temperature of 2°C
at 48 hours versus baseline in the PBS spray control group.
None of the active sprays significantly reduced febrile
response. The PAZC spray group showed a 0.7°C lower
mean body temperature, but this did not reach statistical
significance (p = 0.467). The mean body weight of the
control group dropped by 20 g at 48 hours versus baseline
(fig 3). In contrast, animals that were administered with
PAZC or PAPC spray once daily after virus challenge
showed a significantly reduced weight loss vs control (p =
0.009 and 0.097 respectively). The group with a pre-infec-
tion PAPC treatment regime showed a similar weight loss
Log reduction in Influenza A and avian Influenza titres after 1  min exposure to a pH 3.5 nasal gel spray composition in solu- tion test versus a phosphate buffered saline control Figure 2
Log reduction in Influenza A and avian Influenza titres after 1 
min exposure to a pH 3.5 nasal gel spray composition in solu-
tion test versus a phosphate buffered saline control. PBS: 
Phosphate buffered saline, pH 7.0. PSZH: PCA/succinic acid/
zinc acetate/hydroxypropylmethyl cellulose, pH 3.5.
Table 3: Assignment of animals to treatment and control groups
A s s i g n m e n tn D a y  0 5  m i nD a y  1D a y  2D a y  3D a y  4D a y  5
Group 1 Control 6 virus challenge 0.1 ml PBS 0.1 ml PBS 0.1 ml PBS 0.1 ml PBS 0.1 ml PBS 0.1 ml PBS
Group 2 6 virus challenge 0.1 ml PCPC 0.1 ml PCPC 0.1 ml PCPC 0.1 ml PCPC 0.1 ml PCPC 0.1 ml PCPC
Group 3 6 virus challenge 0.1 ml PCP 0.1 ml PCP 0.1 ml PCP 0.1 ml PCP 0.1 ml PCP 0.1 ml PCP
Log reduction in Influenza A titre after 1 min exposure to  three pH 3.5 nasal spray compositions in solution test versus  a phosphate buffered saline control Figure 1
Log reduction in Influenza A titre after 1 min exposure to 
three pH 3.5 nasal spray compositions in solution test versus 
a phosphate buffered saline control. PBS: Phosphate buffered 
saline, pH 7.0. PAP: PCA/ascorbic acid/phytic acid, pH 3.5. 
PCP: PCA/citric acid/phytic acid, pH 3.5. PAZ: PCA/ascorbic 
acid/zinc acetate, pH 3.5Respiratory Research 2007, 8:38 http://respiratory-research.com/content/8/1/38
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versus control. This group showed a significantly greater
weight loss versus PAZC spray group (p = 0.016).
In the second study, shed virus in nasal lavage samples
peaked at 102.5TCID50 in the control group at 48 hours
(fig 4). In the same group, fever peaked at 0.9°C above
baseline at 48 hours after challenge. The control animals
lost weight vs baseline (mean -65 g at 24 h and -40 g at 48
hours). The mucoadhesive PCPC spray group showed a
mean 2 log TCID50 lower virus shedding versus control (p
= 0.026). The non-mucoadhesive PCP spray group shed
virus titre was not significantly different vs control. The
body temperature of the PCPC group at 48 hours was sig-
nificantly lower versus the PCP group (p = 0.013), but it
did not reach statistical significance versus control (p =
0.166). Weight loss was significantly lower in both treat-
ment groups versus control on days 1 and 2. (fig 5). Over-
all, the non-mucoadhesive spray was less effective than
the mucoadhesive spray. It did not reduce fever on peak
day 2, nor did it reduce shed virus titre.
Discussion
Both Influenza A and Avian A were rapidly inactivated by
contact with compositions of pH 3.5. Our previous work
has shown that pH values close to 3.5 can be achieved in
the human nasal cavity, including the nasopharynx
region, following administration of a pH 3.5 buffered
nasal spray [12]. Infection by enveloped viruses involves
fusion of viral and host cell membranes as a prelude to
transfer of viral genetic material into the cell [13]. Virus
particles are incorporated into endosomes where low pH
causes the haemagglutinin to structurally rearrange its
shape and activate its fusion potential [8,14]. Haemagglu-
tinin is also responsible for binding influenza viruses to
their sialylated cell-surface receptors, so it is conceivable
that premature exposure of virus to low pH in the extracel-
lular environment might induce conformational changes
to glycoprotein spikes on the virus surface, thereby inter-
fering with binding to the cell. Low pH aggregation of
ribonucleocapsids has been reported [15].
The two ferret model studies showed that topical admin-
istration of a low pH intranasal spray at the early stage of
an influenza infection could reduce the severity of the dis-
ease. There was a consistent reduction in weight loss when
the spray was administered shortly after virus challenge. It
remains to be seen whether the products would be as
effective if the spray was administered later in the disease
cycle. The observed efficacy is unlikely to be attributable
to inactivation of the virus challenge dose before the infec-
tion process had begun. Virus was shed throughout the
studies by animals in all treatment groups, albeit at lower
titres than control groups. This indicates that the initial
challenge virus dose was not completely inactivated by
the first treatment.
Mean viral titres in ferret nasal washes in study 2, following  challenge with Influenza A and treatment with pH 3.5 nasal  spray compositions with or without Carbopol 980 gel Figure 4
Mean viral titres in ferret nasal washes in study 2, following 
challenge with Influenza A and treatment with pH 3.5 nasal 
spray compositions with or without Carbopol 980 gel. PBS: 
Phosphate buffered saline, pH 7.0. PCPC: Mucoadhesive for-
mula PCA/citric acid/phytic acid/Carbopol 980, pH 3.5. PCP: 
Non-mucoadhesive formula PCA/citric acid/phytic acid, pH 
3.5. Statistical analysis was performed with ANOVA. Peak 
day 2 PCPC difference vs PBS control, p = 0.026. Peak day 2 
PCP difference vs PBS control, not statistically significant.
Mean body weight change of ferrets in study 1, challenged  with influenza A following pre or post treatment with pH 3.5  gel nasal spray compositions Figure 3
Mean body weight change of ferrets in study 1, challenged 
with influenza A following pre or post treatment with pH 3.5 
gel nasal spray compositions. PAPC: PCA/ascorbic acid/
phytic acid/Carbopol 980, pH 3.5. PAZC: PCA/ascorbic acid/
zinc acetate/Carbopol 980, pH 3.5. Statistical analysis was 
performed with ANCOVA, using the day 0 body weight 
readings as a baseline covariate. Peak day 2 PAPC with post-
challenge dosing, difference vs PBS control, p = 0.097. Peak 
day 2 PAPC with pre-challenge dosing, difference vs PBS con-
trol, not statistically significant. Peak day 2 PAZC with post-
challenge dosing, difference vs PBS control, p = 0.009Respiratory Research 2007, 8:38 http://respiratory-research.com/content/8/1/38
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The second study showed that inclusion of a mucoadhe-
sive gel improved the efficacy of the nasal spray. This
increased effect may have been due to a coating action on
the mucous membranes and an increase in nasal reten-
tion. There is a precedent in the field of allergic rhinitis,
where application of cellulose powder may reduce hay
fever symptoms, presumably by a physical barrier action
[16]. A limitation of nasal delivery is the relatively short
product retention time in the nose due to mucociliary
clearance. The normal residence time of nasally adminis-
tered solutions in humans is around 12–15 min [17]. The
results from the ferret experiments are encouraging since
the product could only be applied once a day due to the
constraints of anaesthetisation. A higher frequency of dos-
ing might have delivered greater reductions in virus titre.
The efficacy of a low pH topical nasal spray against natu-
rally acquired human influenza remains speculative, espe-
cially in light of the paucity of knowledge on the role of
nasal infection in the transmission of influenza [18]. Hay-
den et al [19] showed that intranasal application of a neu-
ramidase inhibitor was effective in a human experimental
influenza model. It is unlikely that the low pH action or
the antiviral effects of any of the ingredients in the formu-
lations tested in this report would have a systemic action.
The formulation is most likely to work topically against
extracellular virus in the nasal cavity.
There is evidence that many influenza infections start with
cold-like nasal symptoms then spread to the lower airway,
whilst others may directly infect the lower airway first
[18]. The relative rates of infection by these routes are not
known. Hand transmission is believed to play an impor-
tant role in influenza infection [20], and since the point of
entry for the hand route is self-inoculation of the eyes or
nose, then a topical nasal spray that delivered an active to
the nasopharynx might have a role to play in reducing
cross infection. The potential benefits of this approach are
likely to be limited to the early stages of an influenza
infection, where it could potentially slow the progression
of the disease.
The non-specificity of low pH for inactivation of respira-
tory viruses means that this approach may be less prone to
resistance development than current antiviral drugs. The
action of the acids is likely to be at multiple points on the
virus surface.
Conclusion
We have demonstrated that low pH nasal sprays can inac-
tivate influenza virus, provided they make contact with
the virus. The action is rapid and non specific. Administra-
tion of low pH compositions to ferrets has shown that
they can influence the course of an experimental influ-
enza infection, with important reductions in severity of
the disease. If human influenza benefits were proven, the
non-drug nature of the approach means that it might be
more readily available to the population at an early stage
of infection than current therapies. We conclude that low
pH gel nasal sprays are a novel approach to treatment of
respiratory virus infections, and that they should be inves-
tigated further for the prophylaxis and treatment of early
influenza in humans.
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lenge with Influenza A and treatment with pH 3.5 nasal spray 
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